ResMed FY13 profit grows 21%
ResMed (ASX:RMD) grew its FY13 profit by 21% to US$307.1 million ($345 million), from 11% higher revenue of US$1.5 billion.
Profit for the year was impacted by ResMed’s recent $25 million payment to the University of Sydney to settle a licensing dispute and support joint research into sleep-disordered breathing.
Excluding this one-off charge, net profit would have grown 27.5% to US$324.8 million. The payment was also responsible for a 5% decline in reported Q4 profit to US$73 million.
Fourth quarter revenue increased 11% to a record US$414.6 million. ResMed CEO Mick Farrell attributed the result to solid sales growth across its key sales regions.
“Revenue in the Americas increased by 11% over the prior year’s quarter to $230.3 million for Q4. Revenue in Europe and Asia-Pac combined reached $184.3 million, an increase of 12% [year on year],” he said.
R&D costs for Q4 grew 12% to US$31.4 million. Without the recent depreciation of the Australian dollar, these costs would have risen by 14%.
ResMed launched several new products during the quarter, including a home variable positive airway pressure (VPAP) device for chronic obstructive pulmonary disease, as well as an online and mobile app to track sleep-disordered breathing treatment progress.
ResMed shares grew 2.44% in Friday’s trading to $5.45 after the results were announced.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
